Cardiff Oncology, Inc.
CRDF- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001213037
In the last 90 days, Cardiff Oncology, Inc. insiders filed 2 open-market purchases and 0 sales; 104 institutions reported holding it in 13F filings for Q2 2026, worth $24.2M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Cardiff Oncology, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 56 | 55 | −1 |
| Shares | 5.39M | 5.29M | −91.0K (−1.7%) |
| Value | $7.58M | $7.84M | +$252.3K (+3.3%) |
New holders (7)
Institutions that held Cardiff Oncology, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| XTX Topco Ltd | 33,453 | $49.5K | 0.01% |
| Citadel Advisors LLC | 27,760 | $41.1K | 0.00% |
| Jane Street Group, LLC | 21,689 | $32.1K | 0.00% |
| Virtu Financial LLC | 21,492 | $32.0K | 0.00% |
| United Bank | 13,000 | $19.2K | 0.00% |
| Security National Bank | 9,767 | $14.5K | 0.00% |
| Vermillion & White Wealth Management Group, LLC | 500 | $740 | 0.00% |
Sold out (8)
Institutions that held Cardiff Oncology, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Assenagon Asset Management S.A. | 84,272 | $117.1K |
| Man Group plc | – | $98.2K |
| Jacobs Levy Equity Management, Inc | 65,558 | $91.1K |
| Gsa Capital Partners LLP | 25,975 | $36.0K |
| Simplex Trading, LLC | 15,551 | $21.0K |
| FMR LLC | 1,574 | $2.19K |
| Tower Research Capital LLC (TRC) | 360 | $500 |
| Global Retirement Partners, LLC | 350 | $413 |